XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.4
Notes Payable
12 Months Ended
Dec. 31, 2022
Notes Payable [Abstract]  
Notes Payable Notes Payable
The Company entered into notes payable as follows as of December 31:
20222021
Note payable at 7% originally due November 2023, now maturing September 30, 2024 (a)
$5,600,000 $5,600,000 
Note payable at 10% interest dated February 28, 2022 and matures the earlier of (i) September 30, 2024 or (ii) the acceleration of the obligations as contemplated under the promissory note including the successful completion of an equity offering of at least $15,000,000 (b)
400,000 — 
Convertible note payable, convertible at $1.60 per share, at 7%, maturing April 4, 2023 (c)
890,000 — 
Note payable with bank, at prime plus 3% interest (6.25% at December 31, 2022) maturing August 11, 2024
2,324,236 3,588,374 
Total Notes Payable9,214,236 9,188,374 
Less: Debt Discount(840,398)(796,565)
$8,373,838 $8,391,809 
(a)On August 12, 2021, the note payable was amended to extend the debt to September 30, 2024. It was determined that under ASC 470, the debt amendment was considered a modification. The amount of the debt discount recorded related to the warrants granted to the note holder was evaluated for characteristics of liability or equity and was determined to be equity under ASC 470 and ASC 480.
(b)On February 28, 2022, the Company was obligated to issue 125,000 shares of common stock as further consideration for making this loan to the Company. The shares were issued in April 2022.
(c)On April 4, 2022, the Company entered into a Securities Purchase Agreement (“SPA”) with Crom. The SPA included (a) a Convertible Promissory Note dated April 4, 2022 in the amount of $1,050,000 at 7% interest per annum. This note matures April 4, 2023 (one-year) and is convertible at a conversion price of $1.60 per share; (b) the issuance of 656,250 warrants that mature April 4, 2027, with an exercise price of $1.84 per share; and (c) the issuance of 1,250,000 common shares at $0.40 per share ($500,000), the proceeds of which were paid to The Buckhout Charitable Remainder Trust for the First Payment. In addition, Crom was issued 125,000 common shares as further inducement to enter into the SPA. The Company analyzed the debt instrument with Crom, under ASC 815-10, and determined that the conversion option should be separated from the host debt instrument (i.e., bifurcated) and classified as a derivative liability, along with the value of the warrants as a derivative liability at the inception date of April 4, 2022. The fair value of the derivative liabilities at inception were reflected as a discount on the note, along with an original issue discount of $50,000, and the discount of $93,000 on the 1,250,000 shares of common stock issued to Crom that had a fair value of $593,000, which exceeded the $500,000 paid by Crom that will be amortized over the life of the note (one year). The derivative liabilities are marked to market each reporting period, and the Company recognized a loss on the change in fair value of the derivative liabilities of 132,000 from April 4, 2022 to December 31, 2022. Furthermore, on February 13, 2023 the Company entered into a series of transactions with Crom to pay off the total amount currently owed under the terms of the convertible promissory note. Refer to subsequent events in Note 16.
Interest expense, which includes amortization of discount, for the years ended December 31, 2022, 2021, and 2020 was $1,874,142, $859,744, and $748,092, respectively.

On April 4, 2022, the Company secured a $950,000 revolving credit facility with Live Oak Bank (“Revolving Credit Facility”). The Revolving Credit Facility matures on March 28, 2029, and draws on it are charged interest at the rate of prime plus 2.75% per annum. Interest is payable monthly. On April 12, 2022, the Company was advanced $300,025 under the Revolving Credit Facility.
Total principal payments on our notes payable for the next three years as of December 31, 2022 are as follows:
2023$2,244,627 
20246,969,609 
2025— 
Total$9,214,236